Interactive Cardiology MCQs 33: Heart Failure
⚡ Advanced Cardiology Series – Part 33
Interactive Cardiology MCQs #33
Post-Graduate Level Masterclass: Heart Failure & Cardiomyopathies
🫀
Live Scoreboard
0/ 25 Correct
Progress:
0/25
Q1
According to the latest universal ACC/AHA/HFSA guidelines, foundational Guideline-Directed Medical Therapy (GDMT) for patients with symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF) relies on four primary pillars. Which of the following best represents this quadruple therapy?
Q2
In a patient newly started on Sacubitril/Valsartan (an ARNI) for HFrEF, how will the circulating levels of B-type Natriuretic Peptide (BNP) and N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) typically change, and why?
Q3
The EMPEROR-Preserved and DELIVER trials revolutionized the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Which class of medications was the first to demonstrate a significant reduction in heart failure hospitalizations and cardiovascular death in this population?
Q4
A 68-year-old male with ischemic cardiomyopathy remains highly symptomatic (NYHA Class III) on maximally tolerated optimal medical therapy. His ECG shows normal sinus rhythm. According to current guidelines, what are the strict criteria for a Class I indication for Cardiac Resynchronization Therapy (CRT-D)?
Q5
Ivabradine is indicated for select patients with HFrEF to reduce heart failure hospitalizations (based on the SHIFT trial). What is the exact mechanism of action of this medication?
Q6
Vericiguat was approved for high-risk patients with worsening HFrEF based on the VICTORIA trial. What is its pharmacological mechanism?
Q7
Under the SCAI (Society for Cardiovascular Angiography and Interventions) clinical staging for Cardiogenic Shock, how is a patient in “Stage C” defined?
Q8
Patients supported with continuous-flow Left Ventricular Assist Devices (cf-LVADs) frequently develop gastrointestinal bleeding. What unique pathophysiological mechanism, caused directly by the continuous-flow physiology, drives this complication?
Q9
A patient with Acute Decompensated Heart Failure presents with cool extremities, altered mentation, and significant peripheral edema. Based on the Forrester Hemodynamic Classification, which subset is this patient in, and what is the primary therapeutic goal?
Q10
In diagnosing Transthyretin Cardiac Amyloidosis (ATTR-CM), a Technetium-99m Pyrophosphate (Tc-99m PYP) scan is highly specific. Under what exact conditions can a positive PYP scan confirm ATTR-CM without requiring an endomyocardial biopsy?
Q11
Based on the ATTR-ACT trial, Tafamidis is the first targeted therapy approved to reduce cardiovascular mortality in Transthyretin Cardiac Amyloidosis (ATTR-CM). What is its specific mechanism of action?
Q12
Mavacamten was recently approved for symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) based on the EXPLORER-HCM trial. What is its mechanism of action, and what is its most critical potential adverse effect requiring strict echocardiographic monitoring?
Q13
According to the DIG trial, what is the specific long-term clinical benefit of adding Digoxin to patients with HFrEF in normal sinus rhythm who remain symptomatic on standard therapy?
Q14
Iron deficiency is highly prevalent in Heart Failure and worsens symptoms independent of anemia. According to the AFFIRM-AHF and IRONMAN trials, what is the guideline-directed threshold for administering Intravenous Iron (e.g., Ferric Carboxymaltose) in HFrEF?
Q15
Peripartum Cardiomyopathy is a rare, life-threatening systolic dysfunction occurring towards the end of pregnancy or months postpartum. Recent evidence suggests that abnormal cleavage of a specific hormone drives the endothelial and myocardial toxicity. Which drug is utilized specifically to block this pathway?
Q16
Stress-induced cardiomyopathy (Takotsubo syndrome) frequently mimics an acute anterior STEMI. What is the pathognomonic echocardiographic or ventriculographic feature of the classic form of this disease?
Q17
A patient migrating from South America presents with progressive heart failure, complete Right Bundle Branch Block (RBBB) with Left Anterior Fascicular Block (LAFB), and a distinct apical aneurysm on echocardiography. What is the most likely infectious etiology?
Q18
Patients with severe HFrEF often exhibit Cheyne-Stokes respiration (a form of Central Sleep Apnea) during sleep. According to the SERVE-HF trial, which intervention is strictly CONTRAINDICATED in this specific population because it increases all-cause and cardiovascular mortality?
Q19
The COAPT and MITRA-FR trials evaluated percutaneous edge-to-edge mitral valve repair (MitraClip) for secondary (functional) mitral regurgitation in HFrEF. The trials yielded conflicting results. Based on current understanding, which patient profile (demonstrated in COAPT) derives the greatest mortality benefit from MitraClip?
Q20
A previously healthy 40-year-old presents in rapidly progressive cardiogenic shock. ECG shows ventricular tachycardia. An echocardiogram shows a thickened, globally hypokinetic myocardium. Endomyocardial biopsy reveals multinucleated giant cells and widespread myocardial necrosis without sarcoid granulomas. What is the diagnosis and appropriate therapy?
Q21
Danon disease is a rare, highly penetrant genetic disorder that phenotypically mimics severe Hypertrophic Cardiomyopathy. Which of the following constellations of findings is the classic hallmark of Danon disease?
Q22
In cardio-oncology, different chemotherapeutic agents cause distinct patterns of cardiotoxicity. How does Type I cardiotoxicity (e.g., Anthracyclines like Doxorubicin) fundamentally differ from Type II cardiotoxicity (e.g., Trastuzumab)?
Q23
The definition and classification of heart failure have been updated. What is the specific Left Ventricular Ejection Fraction (LVEF) range that defines Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)?
Q24
Omecamtiv mecarbil was evaluated in the GALACTIC-HF trial for the treatment of HFrEF. How does this novel agent improve cardiac function?
Q25
In patients with severe Cor Pulmonale (Right Heart Failure) due to WHO Group 2 Pulmonary Hypertension (PH due to Left Heart Disease), which specific pulmonary vasodilator therapy is indicated?
Related Posts
About The Author
Johnson Francis
Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal